Volume 69, Issue 5, Pages (November 2018)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
How to Calculate Your Body Mass Index (BMI)
Volume 64, Issue 3, Pages (March 2016)
Volume 54, Issue 1, Pages (January 2011)
Volume 60, Issue 1, Pages (January 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 65, Issue 3, Pages (September 2016)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 41, Issue 6, Pages (December 2004)
The impact of hepatitis E in the liver transplant setting
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2
Treatment of NAFLD with diet, physical activity and exercise
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Non-invasive diagnosis of non-alcoholic fatty liver disease
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Living donor liver transplantation: is the hype over?
Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity  Samyah Shadid, Michael D Jensen  Clinical Gastroenterology.
Volume 42, Issue 4, Pages (April 2005)
Reply to: “DCD consensus and futility in liver transplantation”
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
European Association for the Study of the Liver  Journal of Hepatology 
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 3, Pages (September 2014)
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?  Andres Duarte-Rojo, Elizabeth Jenny Heathcote,
When the journey from obesity to cirrhosis takes an early start
Volume 69, Issue 4, Pages (October 2018)
EASL Clinical Practice Guidelines: Wilson’s disease
Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva 
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 69, Issue 6, Pages (December 2018)
Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual 
Economics of chronic hepatitis B and hepatitis C
Volume 70, Issue 1, Pages (January 2019)
Coffee and tea breaks for liver health
Volume 65, Issue 2, Pages (August 2016)
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J,
Volume 57, Issue 5, Pages (November 2012)
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 67, Issue 5, Pages (November 2017)
Portal vein thrombosis, cirrhosis, and liver transplantation
Joint Effects of Body Weight and Alcohol on Elevated Serum Alanine Aminotransferase in the United States Population  Constance E. Ruhl, James E. Everhart 
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
Changes in the 24-h plasma cortisol rhythm in patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
A 360-degree overview of paediatric NAFLD: Recent insights
Volume 71, Issue 2, Pages (August 2019)
Cystic fibrosis and pregnancy in the modern era: A case control study
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 69, Issue 5, Pages 1155-1163 (November 2018) An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers  Arianna Mazzotti, Maria Turchese Caletti, Lucia Brodosi, Silvia Di Domizio, Maria Luisa Forchielli, Salvatore Petta, Elisabetta Bugianesi, Giampaolo Bianchi, Giulio Marchesini  Journal of Hepatology  Volume 69, Issue 5, Pages 1155-1163 (November 2018) DOI: 10.1016/j.jhep.2018.07.013 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2018 69, 1155-1163DOI: (10. 1016/j. jhep. 2018 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Percentage weight loss in patients with NAFLD enrolled in the web-based (grey circles) and the group-based (white circles) lifestyle intervention programs. The number of cases achieving the 10% weight loss target at different time points is reported in the Table. Note that no differences between groups were demonstrated at any time point. NAFLD, non-alcoholic fatty liver disease. Journal of Hepatology 2018 69, 1155-1163DOI: (10.1016/j.jhep.2018.07.013) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Time course of ALT levels in patients with NAFLD enrolled in the web-based (grey circles) and the group-based (white circles) lifestyle intervention programs. In the Table, the numerator gives the number of cases with ALT decreased within normal range following treatment (the total number with normal ALT is in brackets), the denominator is the total number of cases, with the total percentage with normal ALT at different time points in square brackets. ALT, alanine aminotransferase; NAFLD, non-alcoholic fatty liver disease. Journal of Hepatology 2018 69, 1155-1163DOI: (10.1016/j.jhep.2018.07.013) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Box plot representation of the time course of surrogate markers of steatosis and fibrosis in individuals enrolled in the group-based (white boxes) and web-based (grey boxes) lifestyle intervention programs. For all surrogate markers, ANOVA reveals significant differences between treatment categories (p <0.001). Journal of Hepatology 2018 69, 1155-1163DOI: (10.1016/j.jhep.2018.07.013) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Association of web-based lifestyle intervention with weight loss ≥10% initial body weight and ALT levels within normal values, compared with group-based lifestyle intervention, at 12-month (closed squares) and 24-month follow-up (closed circles). *Adjusted for age, sex, education, employment status, baseline BMI and ALT, and the presence of T2DM. ^Adjusted as above + weight change from baseline. ALT, alanine aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus. Journal of Hepatology 2018 69, 1155-1163DOI: (10.1016/j.jhep.2018.07.013) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions